Conduit Pharmaceuticals I... (CDT)
NASDAQ: CDT
· Real-Time Price · USD
1.62
-0.05 (-2.99%)
At close: Aug 15, 2025, 3:59 PM
1.71
5.56%
After-hours: Aug 15, 2025, 07:24 PM EDT
Conduit Pharmaceuticals Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 |
| Period Ending | Jun 29, 2025 | Mar 30, 2025 | Dec 31, 2024 | Sep 29, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 |
Revenue | 1.33B | 654.93M | 1.19B | 1.19B | 535.67M | 535.67M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | 1.65B | 1.62B | 1.95B | 1.12B | 711.61M | 334.08M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit | 752.2M | 720.44M | 922.22M | 672.41M | 428.4M | 201.6M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Income | 65.9M | -16.47M | -15.42M | -12.8M | -7.42M | -6M | -4.56M | -5.34M | -5.84M | -4.4M | -3.18M | -1.51M | -574.38K | -295.38K | -4.38K |
Interest Income | 10K | 12K | 13K | 41K | 41K | 314.29K | 969.52K | 2.1M | 2.71M | 2.63M | 1.97M | 801.5K | 191.59K | n/a | n/a |
Pretax Income | 52.66M | -19.4M | -17.8M | -13.62M | -5.17M | -1.52M | 361K | -4.49M | -7.43M | -5.79M | -4.42M | -1.36M | -399.22K | -311.38K | -4.38K |
Net Income | 46.99M | -19.4M | -17.82M | -13.64M | -5.19M | -1.54M | 360K | -4.49M | -7.43M | -5.82M | -4.45M | -1.39M | -429.38K | -311.38K | -4.38K |
Selling & General & Admin | 140.27M | 11.46M | 11.59M | 9.46M | 7.18M | 5.78M | 4.96M | 5.88M | 6.22M | 4.78M | 3.07M | 1.35M | 574.8K | 295.38K | 4.38K |
Research & Development | 38.47M | 4.56M | 3.38M | 3.34M | 243K | 218K | 90K | -47K | 111K | 111K | 111K | 158K | n/a | n/a | n/a |
Other Expenses | -190K | -2.4M | -2.7M | -2.7M | 405K | 2.59M | 2.8M | 2.8M | -303K | -280K | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 178.55M | 15.83M | 14.97M | 12.8M | 8.06M | 5.81M | 4.37M | 5.15M | 5.01M | 4.4M | 3.18M | 1.51M | 574.8K | 295.38K | 4.38K |
Interest Expense | -10.75M | 1.56M | 1.51M | 878K | 615K | 535K | 421K | 91K | 44K | 5K | n/a | n/a | n/a | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | 829K | 829K | 829K | 829K | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 592.62M | 16.47M | 15.42M | 12.8M | 8.06M | 5.81M | 4.37M | 5.15M | 5.01M | 4.4M | 3.18M | 1.51M | 574.8K | 295.38K | 4.38K |
Income Tax Expense | -65.81M | -60.14M | -60.14M | -60.15M | 47K | 48K | 48K | 48K | 1K | 29.7K | 29.7K | 29.7K | 29.7K | n/a | n/a |
Shares Outstanding (Basic) | 39.51M | 2.01M | 2.03M | 2.18M | 1.85M | 1.85M | 1.85M | 32.71K | 36.21K | 36.21K | 432.15K | 1.81M | 432.15K | 36.21K | 432.13K |
Shares Outstanding (Diluted) | 40M | 2.04M | 2.06M | 2.18M | 1.85M | 1.85M | 1.99M | 1.65M | 36.21K | 36.21K | 432.15K | 1.81M | 432.15K | 36.21K | 432.13K |
EPS (Basic) | 32.54 | -2.07K | -3.54K | -3.54K | -3.54K | -1.49K | -91.84 | -100 | -127.6 | -80.07 | -42.27 | -35.08 | -8.68 | -8.41 | -0.01 |
EPS (Diluted) | 6.63 | -2.09K | -3.56K | -3.54K | -3.52K | -1.44K | -42.81 | -49.4 | -95.8 | -80.07 | -42.27 | -35.08 | -8.68 | -8.41 | -0.01 |
EBITDA | 67.17M | -17.33M | -15.51M | -12.4M | -4.12M | -553K | 730K | -2.72M | -5.67M | -4.06M | -2.64M | -1.3M | -346.21K | -258.38K | -4.38K |
EBIT | -12.71M | -17.97M | -16.44M | -12.88M | -4.55M | -984K | 777K | -2.68M | -5.67M | -4.06M | -2.69M | -1.36M | -399.22K | -311.38K | -4.38K |
Depreciation & Amortization | 647K | 647K | 27.44M | 27.04M | 26.99M | 27.11M | 167.9K | 178.96K | 245.63K | 209.61K | 168.03K | 113.15K | 86.06K | n/a | n/a |